KOD — Kodiak Sciences Inc.
$87.63+2.16%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for KOD in the TickerWise workspace.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 109
- Website: https://kodiak.com
Latest SEC filings for KOD
Latest KOD news
- Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026 Read article
- Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study Read article
- Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Acquires 33,726 Shares of Company Stock Read article
- A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? Read article
- KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears Read article
- Kodiak Sciences Inc. (NASDAQ: KOD) Advances Zenkuda Toward Filing Read article
- Why Kodiak Sciences Skyrocketed Today Read article
- Kodiak Sciences skyrockets as Zenkuda, tabirafusp excel in late-stage wet AMD trial Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.